

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry.

This journal is © The Royal Society of Chemistry 2015

Organic & Biomolecular Chemistry

Simple and Efficient one-pot multi-step strategy for synthesis of 2-substituted (1,2,5-triarylpyrrolo[3,2-c]pyridin-3-yl)-*N*- arylacetamide derivatives in water

Chunmei Li,^{a,b} Xiaopeng Yang,^a Furen Zhang,^{*a} Chenze Qi^a and Zhenlu Shen^{*b}

^aSchool of Chemistry and Chemical Engineering, Zhejiang Key Laboratory of Alternative Technologies for Fine Chemicals Process, Shaoxing University, Shaoxing, Zhejiang Province 312000, China.

^bCollege of Chemical Engineering, Zhejiang University of Technology, Hangzhou Zhejiang Province 310032, China.

Fax: 86 (575) 88345682; Tel: 86 (575) 88345682; E-mail: frzhang@usx.edu.cn (F. R. Zhang); zhenlushen@zjut.edu.cn (Z. L. Shen)

Electronic Supplementary Information (ESI)

Supplementary Information Available: complete product characterization data, analytical details.

Table of Contents

1. General information.....	S3
2. X-ray Crystallography.....	S3
3. General procedure for the synthesis of 5.....	S3
4. General procedure for the synthesis of 7.....	S4
5. General procedure for the synthesis of 9.....	S4
6. Spectral data of the compounds.....	S4
7. ¹H and ¹³C NMR spectra.....	S15

General information

All reagents were purchased from commercial suppliers and were used without further purification. The reactions were monitored by thin-layer chromatography (TLC) analysis using silica gel (GF254) plates. ¹H NMR spectra were recorded on a 400 MHz instrument (Bruker Avance 400 Spectrometer). Chemical shifts (δ) are given in ppm relative to TMS as the internal reference, with coupling constants (J) in Hz. ¹³C NMR spectra were recorded at 100 MHz. Chemical shift were reported in ppm with the internal chloroform signal at 77.7 ppm and dimethyl sulphoxide signal at 39.9 ppm as a standard. HRMS (ESI) was measured with a Waters XEVO G2-XS QTOF/H-CLASS instrument. Single-crystal X-ray diffraction measurement was carried out on a Rigaku Saturn CCD diffractometer at 100(2) K using graphite monochromated Mo K α radiation ($\lambda = 0.71073$ Å). The structure was solved by direct methods and refined by full-matrix least squares on F^2 using the SHELXTL-97 program package.

X-ray Crystallography

Single-crystal X-ray diffraction measurement was carried out on a Rigaku Saturn CCD diffractometer at 100.00(10) K using graphite monochromated CuK α radiation ($\lambda = 1.54184$). An empirical absorption correction was applied using the SADABS program. The structure was solved by direct methods and refined by full-matrix least squares on F^2 using the SHELXTL-97 program package.

General procedure for the synthesis of products 5.

Typically, 6-methyl-1-aryl-4-(phenylamino)pyridin-2(1*H*)-one **1** (0.4 mmol), 2,2-dihydroxy-1-phenylethan-1-one **2** (0.4 mmol), and Meldrum acid **3** (0.4 mmol) were introduced in a 10-mL reaction vial with acetic acid (0.04 mmol) and water (3 mL). Subsequently, the reaction vial was stirred and heated at 80 °C. The reaction was monitored by TLC until conversion of the substrates was complete about 2 hours. The mixture was cooled to room temperature. The resulted precipitate was filtered and the crude products were further purified by recrystallization [from the mixture of hot 95% ethanol and *N,N*-dimethylformamide](#) to give the pure products **5**.

General procedure for the synthesis of products 7.

Similarly, 6-methyl-1-aryl-4-(phenylamino)pyridin-2(1*H*)-one **1** (0.4 mmol), 2,2-dihydroxy-1-phenylethan-1-one **2** (0.4 mmol), and Meldrum acid **3** (0.4 mmol) were introduced in a 10-mL reaction vial with acetic acid (0.04 mmol) and water (3 mL). Subsequently, the reaction vial was stirred and heated 80 °C for about 2 hours. Then, alcohol **6** (0.8 mmol) was added the mixture and stirred for another 2 hours. The mixture was cooled and the precipitate was filtered. The crude products were further purified by recrystallization from hot 95% ethanol to give the pure products **7**.

General procedure for the synthesis of products 9.

Similarly, 6-methyl-1-aryl-4-(phenylamino)pyridin-2(1*H*)-one **1** (0.4 mmol), 2,2-dihydroxy-1-phenylethan-1-one **2** (0.4 mmol), and Meldrum acid **3** (0.4 mmol) were introduced in a 10-mL reaction vial with acetic acid (0.04 mmol) and water (3 mL). Subsequently, the reaction vial was stirred and heated 80 °C for about 2 hours. Then, alcohol **6** (0.8 mmol) was added the mixture and stirred for another 2 hours. Lastly, amine **8** (0.4 mmol) was added above mixture for about 4 hours indicated by TLC. The crude products were further purified by recrystallization [from the mixture of hot 95% ethanol and *N,N*-dimethylformamide](#) to give the pure desired products **9**.

Spectral data of the compounds

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*c*]pyridin-3-yl)acetic acid (**5a**)

Pale yellow solid; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.54-7.62 (m, 3H, ArH), 7.45 (t, *J* = 8.0 Hz, 5H, ArH), 7.29-7.30 (m, 2H, ArH), 7.17-7.22 (m, 4H, ArH), 6.39 (s, 1H, CH), 3.78 (s, 2H, CH₂), 2.05 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.3, 162.8, 141.0, 140.5, 138.2, 136.5, 136.1, 132.3, 131.6, 129.9, 129.8, 129.2, 128.6, 128.2, 128.0, 127.6, 122.6, 112.5, 112.0, 96.6, 33.9, 22.1; HRMS (ESI) *m/z* calcd for C₂₈H₂₂BrN₂O₃ [M + H]⁺: 513.0808, found: 513.0811.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-di-*p*-tolyl-4,5-dihydro-1*H*-pyrrolo[3,2-*c*]pyridin-3-yl)acetic acid (**5b**)

White powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 13.90 (s, 1H, OH),

7.34-7.41 (m, 4H, ArH), 7.13-7.19 (m, 6H, ArH), 7.01 (s, 2H, ArH), 6.31 (s, 1H, CH), 3.72 (s, 2H, CH₂), 2.43 (s, 3H, CH₃), 2.39 (s, 3H, CH₃), 2.01 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.2, 162.5, 141.2, 141.3, 140.5, 140.4, 140.3, 138.2, 136.5, 136.1, 132.3, 131.6, 129.2, 128.6, 128.1, 128.0, 127.6, 96.6, 33.9, 22.6, 22.1; HRMS (ESI) m/z calcd for C₃₀H₂₆BrN₂O₃ [M + H]⁺: 541.1121, found: 541.1116.

2-(1,5-bis(4-fluorophenyl)-6-methyl-4-oxo-2-phenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetic acid (5c)

Pale yellow solid; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.28-7.39 (m, 8H, ArH), 7.11-7.18 (m, 8H, ArH), 6.35 (s, 1H, CH), 3.79 (s, 2H, CH), 2.07 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.2, 162.9, 162.6 (¹J_{CF} = 247.8 Hz), 162.0 (¹J_{CF} = 248.0 Hz), 140.8, 140.2, 137.6, 134.1 (⁴J_{CF} = 2.8 Hz), 132.7 (⁴J_{CF} = 2.8 Hz), 130.9, 130.1 (³J_{CF} = 8.6 Hz), 129.3 (³J_{CF} = 8.7 Hz), 128.8, 128.5, 128.3, 127.9, 116.9 (²J_{CF} = 22.9 Hz), 116.6 (²J_{CF} = 22.9 Hz), 112.4, 111.7, 96.5, 33.8, 22.1; HRMS (ESI) m/z calcd for C₂₈H₂₁F₂N₂O₃ [M + H]⁺: 471.1515, found: 471.1511.

2-(1,5-dibenzyl-2-(4-bromophenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetic acid (5d)

Pale yellow solid; Mp: 230-232 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.59 (d, *J* = 8.4 Hz, 2H, ArH), 7.28-7.37 (m, 8H, ArH), 7.17 (d, *J* = 6.8 Hz, 2H, ArH), 6.93 (d, *J* = 7.6 Hz, 2H, ArH), 5.51 (s, 2H, CH₂), 5.18 (s, 2H, CH₂), 3.74 (s, 2H, CH₂), 2.37 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.4, 168.4, 140.2, 140.1, 136.6, 136.5, 136.4, 132.5, 132.0, 129.1, 128.9, 127.9, 127.5, 126.3, 125.7, 123.5, 112.2, 111.3, 97.0, 48.0, 47.2, 34.0, 21.3; HRMS (ESI) m/z calcd for C₃₀H₂₆BrN₂O₃ [M + H]⁺: 541.1121, found: 541.1129.

2-(2-(4-bromophenyl)-1,5-dibutyl-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetic acid (5e)

Gray powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.62 (d, *J* = 8.4 Hz, 2H, ArH), 7.28 (d, *J* = 8.4 Hz, 2H, ArH), 6.37 (s, CH, ArH), 4.12 (t, *J* = 7.6 Hz, 2H, CH₂), 3.88 (d, *J* = 7.2 Hz, 2H, CH₂), 3.58 (s, 2H, CH₂), 2.51 (s, 3H, CH₃), 1.66-1.70 (m, 2H, CH₂), 1.40-1.47 (m, 4H, CH₂), 1.04-1.10 (m, 2H, CH₂), 0.96 (t, *J* = 7.2 Hz, 3H, CH₃), 0.75 (t, *J* = 7.2 Hz, 2H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.6, 162.0, 139.3, 138.8, 135.8, 132.5, 132.0, 128.5, 123.2, 112.2, 110.8, 96.6, 44.4, 44.1, 32.8, 32.3, 31.2, 21.1, 20.3, 19.8, 13.8, 13.5; HRMS (ESI) m/z calcd for C₂₄H₃₀BrN₂O₃ [M + H]⁺:

473.1434, found: 473.1433.

2-(6-methyl-4-oxo-1,2,5-triphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetic acid (5f)

White solid; Mp: 285-286 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.49-7.61 (m, 5H, ArH), 7.40-7.46 (m, 4H, ArH), 7.31-7.34 (m, 9H, ArH), 7.24-7.28 (m, 2H, ArH), 7.19 (d, *J* = 7.6 Hz, 2H, ArH), 6.40 (s, 1H, CH), 3.81 (s, 2H, CH), 2.06 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.5, 162.9, 140.9, 140.1, 138.4, 137.5, 136.9, 131.0, 129.9, 129.6, 129.5, 129.4, 129.1, 129.0, 128.8, 128.4, 128.1, 127.8, 127.6, 127.5, 112.6, 111.7, 96.7, 33.9, 22.2; HRMS (ESI) *m/z* calcd for C₂₈H₂₃N₂O₃ [M + H]⁺: 435.1703, found: 435.1698.

2-(2-(4-fluorophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetic acid (5g)

Pale yellow solid; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.54-7.62 (m, 3H, ArH), 7.42-7.46 (m, 3H, ArH), 7.29-7.33 (m, 5H, ArH), 7.18 (d, *J* = 6.8 Hz, 2H, ArH), 7.03 (t, *J* = 8.8 Hz, 2H, ArH), 6.39 (s, 1H, CH), 3.78 (s, 2H, CH), 2.05 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.4, 162.8 (¹*J*_{CF} = 247.4 Hz), 140.8, 140.3, 138.3, 136.6, 136.3, 132.7 (³*J*_{CF} = 8.2 Hz), 129.9, 129.6, 129.2, 128.5, 128.3, 127.6, 125.2, 125.1, 115.5 (²*J*_{CF} = 22.0 Hz), 115.4, 112.4, 111.7, 96.6, 33.9, 22.1; HRMS (ESI) *m/z* calcd for C₂₈H₂₂FN₂O₃ [M + H]⁺: 453.1609, found: 453.1605.

ethyl 2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7a)

Brown powder; Mp: 246-248 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.52 (t, *J* = 7.2 Hz, 2H, ArH), 7.38-7.46 (m, 7H, ArH), 7.28 (t, *J* = 5.6 Hz, 2H, ArH), 7.19 (d, *J* = 7.2 Hz, 2H, ArH), 7.05 (d, *J* = 8.0 Hz, 2H, ArH), 6.16 (s, 1H, CH), 4.12-4.18 (m, 2H, CH₂), 3.98 (s, 2H, CH₂), 1.95 (s, 3H, CH₃), 1.22 (m, *J* = 6.8 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.5, 161.1, 140.0, 139.3, 137.0, 134.4, 131.8, 131.5, 129.7, 129.5, 129.4, 128.8, 128.3, 127.9, 127.7, 122.0, 113.6, 112.8, 94.5, 60.7, 30.8, 22.3, 14.2; HRMS (ESI) *m/z* calcd for C₃₀H₂₆BrN₂O₃ [M + H]⁺: 541.1121, found: 541.1123.

methyl 2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7b)

Yellow powder; Mp: 238-240 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.53 (t, *J* = 8.0

Hz, 2H, ArH), 7.45 (t, $J = 7.2$ Hz, 1H, ArH), 7.35-7.42 (m, 3H, ArH), 7.26-7.29 (m, 5H, ArH), 7.17-7.22 (m, 4H, ArH), 6.19 (s, 1H, CH), 4.01 (s, 2H, CH₂), 3.69 (s, 3H, OCH₃), 1.96 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 173.1, 161.2, 139.8, 139.7, 139.4, 137.2, 135.8, 130.6, 130.4, 129.5, 129.2, 128.9, 128.3, 128.2, 127.7, 113.0, 112.7, 94.6, 52.0, 30.8, 22.2; HRMS (ESI) m/z calcd for C₂₉H₂₄BrN₂O₃ [M + H]⁺: 527.0965, found: 527.0966.

isopropyl 2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7c)

Yellow powder; Mp: 228-230 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.52 (t, $J = 7.6$ Hz, 2H, ArH), 7.33-7.46 (m, 4H, ArH), 7.25-7.29 (m, 5H, ArH), 7.16-7.21 (m, 4H, ArH), 6.19 (s, 1H, CH), 5.00-5.03 (m, 1H, CH), 4.00 (s, 2H, CH₂), 1.96 (s, 3H, CH₃), 1.21 (t, $J = 6.0$ Hz, 6H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.1, 161.2, 139.7, 139.5, 139.4, 137.3, 135.7, 130.8, 130.4, 129.5, 129.2, 128.9, 128.3, 128.1, 127.7, 127.6, 113.3, 112.8, 94.6, 67.8, 31.1, 25.3, 22.2, 21.8; HRMS (ESI) m/z calcd for C₃₁H₂₈BrN₂O₃ [M + H]⁺: 555.1278, found: 555.1283.

tert-butyl 2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7d)

Pale yellow solid; Mp: 289-290 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.51 (t, $J = 7.6$ Hz, 2H, ArH), 7.37-7.46 (m, 6H, ArH), 7.25-7.29 (m, 2H, ArH), 7.19 (d, $J = 6.8$ Hz, 2H, ArH), 7.06 (d, $J = 6.8$ Hz, 2H, ArH), 6.15 (s, 1H, CH), 3.95 (s, 2H, CH₂), 1.95 (s, 3H, CH₃), 1.42 (s, 9H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 171.8, 139.9, 139.8, 139.4, 137.1, 131.8, 131.3, 130.0, 129.4, 128.9, 128.2, 127.8, 127.7, 121.8, 114.3, 112.7, 94.4, 80.4, 31.7, 28.0, 22.2; HRMS (ESI) m/z calcd for C₃₂H₃₀BrN₂O₃ [M + H]⁺: 569.1434, found: 569.1434.

ethyl 2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-di-p-tolyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7e)

Pale yellow crystal; Mp: 258-260 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.39 (d, $J = 8.0$ Hz, 2H, ArH), 7.30 (t, $J = 8.0$ Hz, 3H, ArH), 7.20 (d, $J = 8.0$ Hz, 2H, ArH), 7.13 (d, $J = 8.0$ Hz, 2H, ArH), 7.06 (t, $J = 4.4$ Hz, 2H, ArH), 6.13 (s, 1H, CH), 4.12-4.16 (m, 2H, CH₂), 3.97 (s, 1H, CH), 2.41 (d, $J = 10.0$ Hz, 6H, CH₃), 1.95 (s, 3H, CH₃), 1.22 (t, $J = 7.2$ Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.5, 161.2, 140.0, 138.1, 137.8,

136.7,134.4, 131.9, 131.4, 130.2, 130.0, 129.8, 128.5, 127.9, 127.4, 121.8, 113.3, 112.6, 94.4, 60.7, 30.8, 22.2, 21.2, 14.2; HRMS (ESI) m/z calcd for $C_{32}H_{30}BrN_2O_3$ $[M + H]^+$: 569.1434, found: 569.1429.

ethyl 2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-di-o-tolyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7f)

Brown solid; Mp: 170-172 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 7.26-7.38 (m, 7H, ArH), 7.18-7.23 (m, 3H, ArH), 7.05-7.08 (m, 2H, ArH), 5.87 (s, 1H, CH), 4.12-4.18 (m, 2H, CH_2), 3.94-4.06 (m, 2H, CH_2), 2.13 (d, $J = 4.4$ Hz, 3H, CH_3), 1.96 (d, $J = 4.0$ Hz, 3H, CH_3), 1.86 (s, 3H, CH_3), 1.20-1.25 (m, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 172.4, 160.4, 140.1, 139.6, 138.5, 136.6, 136.5, 136.1, 136.0, 134.7, 131.4, 131.2, 131.0, 129.8, 129.7, 129.2, 129.0, 128.7, 128.6, 127.1, 126.8, 121.9, 115.3, 113.2, 112.7, 94.4, 60.7, 30.9, 21.7, 17.7, 17.6, 14.2; HRMS (ESI) m/z calcd for $C_{32}H_{30}BrN_2O_3$ $[M + H]^+$: 569.1434, found: 569.1432.

ethyl 2-(2-(4-bromophenyl)-1,5-bis(2,4-dimethylphenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7g)

Yellow solid; Mp: 222-224 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 7.37 (d, $J = 8.4$ Hz, 2H, ArH), 7.03-7.18 (m, 8H, ArH), 5.86 (s, 1H, CH), 4.12-4.15 (m, 2H, CH_2), 3.99 (s, 2H, CH_2), 2.38 (d, $J = 2.4$ Hz, 6H, CH_3), 2.08 (d, $J = 4.0$ Hz, 3H, CH_3), 1.87-1.92 (s, 6H, CH_3), 1.19-1.24 (m, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 172.5, 172.4, 160.6, 140.2, 139.7, 138.8, 138.3, 136.0, 135.8, 135.6, 134.7, 133.4, 132.0, 131.8, 131.5, 131.3, 129.9, 128.9, 128.4, 127.8, 127.5, 121.8, 113.0, 112.6, 94.4, 60.6, 30.9, 21.7, 21.2, 17.6, 17.5, 14.2; HRMS (ESI) m/z calcd for $C_{34}H_{34}BrN_2O_3$ $[M + H]^+$: 597.1747, found: 597.1754.

ethyl 2-(2-(4-bromophenyl)-1,5-bis(4-fluorophenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7h)

Yellow powder; Mp: >300 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 7.41 (d, $J = 8.4$ Hz, 2H, ArH), 7.11-7.23 (m, 8H, ArH), 7.04 (d, $J = 8.4$ Hz, 2H, ArH), 6.11 (s, 1H, CH), 4.12-4.18 (m, 2H, CH_2), 3.94 (s, 2H, CH_2), 1.96 (s, 3H, CH_3), 1.23 (t, $J = 8.0$ Hz, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 172.4, 162.3 ($^1J_{CF} = 242.3$ Hz), 162.2 ($^1J_{CF} = 242.5$ Hz), 140.0, 135.1 ($^4J_{CF} = 3.0$ Hz), 134.6 ($^4J_{CF} = 3.0$ Hz), 132.9, 131.9, 131.6, 130.6, 130.5 ($^3J_{CF} = 9.0$ Hz), 129.4 ($^3J_{CF} = 8.9$ Hz), 122.2, 116.5 ($^2J_{CF} = 22.8$ Hz), 116.4 ($^2J_{CF} =$

22.7 Hz), 113.6, 112.7, 94.5, 60.8, 30.8, 22.3, 14.2; HRMS (ESI) m/z calcd for $C_{30}H_{24}BrF_2N_2O_3$ $[M + H]^+$: 577.0933, found: 577.0929.

ethyl 2-(2-(4-bromophenyl)-1,5-bis(2-fluorophenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7i)

Yellow solid; Mp: 245-246 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 7.39-7.48 (m, 5H, ArH), 7.19-7.36 (m, 7H, ArH), 7.08 (d, $J = 8.4$ Hz, 2H, ArH), 6.03 (s, 1H, CH), 4.12-4.17 (m, 2H, CH_2), 3.80-4.02 (m, 1H, CH_2), 7.75-3.80 (m, 1H, CH_2), 1.99 (s, 3H, CH_3), 1.22 (t, $J = 4.0$ Hz, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 172.2, 172.1, 160.4 ($^1J_{CF} = 242.5$ Hz), 160.2 ($^1J_{CF} = 242.4$ Hz), 140.6, 140.5 ($^4J_{CF} = 2.1$ Hz), 140.1 ($^4J_{CF} = 2.7$ Hz), 134.9, 131.5, 130.9 ($^3J_{CF} = 7.5$ Hz), 130.5, 130.4, 130.3, 130.2 ($^3J_{CF} = 6.6$ Hz), 129.3, 124.9, 122.3, 117.0 ($^2J_{CF} = 22.5$ Hz), 116.8 ($^2J_{CF} = 22.4$ Hz), 113.8, 112.8, 94.7, 94.6, 60.7, 30.8, 21.5, 14.1; HRMS (ESI) m/z calcd for $C_{30}H_{24}BrF_2N_2O_3$ $[M + H]^+$: 577.0933, found: 577.0932.

ethyl 2-(2-(4-bromophenyl)-1,5-bis(3-chlorophenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7j)

Yellow crystal; Mp: 275-276 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 7.42-7.49 (m, 4H, ArH), 7.27-7.38 (m, 2H, ArH), 7.28 (d, $J = 6.8$ Hz, 3H, ArH), 7.17 (d, $J = 6.8$ Hz, 1H, ArH), 7.01-7.06 (m, 3H, ArH), 6.15 (s, 1H, CH), 4.13-4.19 (m, 2H, CH_2), 3.93 (s, 2H, CH_2), 1.99 (s, 3H, CH_3), 1.23 (m, $J = 6.8$ Hz, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 172.3, 160.8, 140.3, 139.9, 138.0, 135.1, 135.0, 134.5, 131.8, 131.7, 130.5, 129.3, 129.1, 128.8, 128.3, 127.7, 127.3, 126.1, 122.3, 114.1, 112.8, 94.5, 60.8, 30.8, 22.2, 14.2; HRMS (ESI) m/z calcd for $C_{30}H_{24}BrCl_2N_2O_3$ $[M + H]^+$: 609.0342, found: 609.0344.

ethyl 2-(6-methyl-4-oxo-1,2,5-triphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetate (7k).

Brown solid; Mp: 261-262 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 7.49-7.53 (m, 2H, ArH), 7.31-7.44 (m, 6H, ArH), 7.23-7.25 (m, 5H, ArH), 7.15-7.20 (m, 4H, ArH), 6.16 (s, 1H, CH), 4.10-4.15 (m, 2H, CH_2), 3.98 (s, 2H, CH_2), 1.94 (m, 3H, CH_3), 1.20 (t, $J = 3.2$ Hz, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 172.6, 139.6, 139.4, 137.3, 130.7, 130.4, 129.5, 129.2, 128.9, 128.3, 128.1, 127.7, 127.6, 113.1, 94.6, 60.6, 30.9, 22.2, 14.1; HRMS (ESI) m/z calcd for $C_{30}H_{27}N_2O_3$ $[M + H]^+$: 463.2016, found: 463.2011.

ethyl 2-(2-(4-fluorophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-

pyrrolo[3,2-c]pyridin-3-yl)acetate (7l).

Pale yellow crystal; Mp: 256-258 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 7.46-7.51 (m, 2H, ArH), 7.36-7.44 (m, 4H, ArH), 7.26-7.29 (m, 3H, ArH), 7.14-7.20 (m, 4H, ArH), 6.96 (d, *J* = 8.4 Hz, 2H, ArH), 6.17 (s, 1H, CH), 4.12-4.17 (m, 2H, CH₂), 3.97 (s, 2H, CH₂), 1.95 (s, 3H, CH₃), 1.22 (m, *J* = 6.8 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 172.5, 161.1 (¹*J*_{CF} = 247.2 Hz), 139.7 (⁴*J*_{CF} = 2.0 Hz), 139.4, 137.1, 134.7, 132.1 (³*J*_{CF} = 8.0 Hz), 129.9, 129.6, 129.5, 129.3, 128.9, 128.3, 127.8, 127.7, 126.8, 115.3 (²*J*_{CF} = 22.0 Hz), 113.2, 112.6, 94.6, 60.7, 30.8, 22.2, 14.2; HRMS (ESI) *m/z* calcd for C₃₀H₂₆FN₂O₃ [M + H]⁺: 481.1922, found: 481.1933.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-phenylacetamide (9a).

White powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.23 (s, 1H, NH), 7.58-7.67 (m, 5H, ArH), 7.44-7.48 (m, 7H, ArH), 7.28-7.34 (m, 4H, ArH), 7.18-7.19 (m, 2H, ArH), 7.04-7.06 (m, 1H, ArH), 6.29 (s, 1H, CH), 3.81 (s, 2H, CH₂), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.2, 162.2, 140.8, 140.1, 139.6, 139.2, 136.9, 135.4, 132.7, 131.3, 129.9, 129.6, 128.9, 128.7, 128.5, 128.4, 128.2, 127.7, 123.1, 122.3, 119.4, 114.4, 112.2, 95.6, 34.9, 22.1; HRMS (ESI) *m/z* calcd for C₃₄H₂₇BrN₃O₂ [M + H]⁺: 588.1281, found: 588.1277.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9b).

White powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.10 (s, 1H, NH), 7.55-7.63 (m, 3H, ArH), 7.42-7.48 (m, 9H, ArH), 7.27-7.31 (m, 3H, ArH), 7.07-7.17 (m, 4H, ArH), 6.26 (s, 1H, CH), 3.78 (s, 2H, CH₂), 2.29 (s, 3H, CH₃), 2.00 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.0, 162.2, 140.8, 140.1, 139.2, 137.0, 136.9, 135.4, 132.7, 132.5, 131.3, 129.8, 129.6, 129.2, 128.9, 128.5, 128.4, 128.2, 127.7, 122.2, 119.3, 114.6, 112.2, 95.6, 34.8, 22.1, 20.9; HRMS (ESI) *m/z* calcd for C₃₅H₂₉BrN₃O₂ [M + H]⁺: 602.1438, found: 602.1447.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(4-methoxyphenyl)acetamide (9c).

White solid; Mp: 286-288 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.9 (s, 1H, NH), 7.65 (t, *J* = 7.6 Hz, 2H, ArH), 7.18 (d, *J* = 7.2 Hz, 1H, ArH), 7.53 (d, *J* = 8.4 Hz, 2H,

ArH), 7.31 (d, $J = 7.6$ Hz, 2H, ArH), 7.18 (d, $J = 6.8$ Hz, 2H, ArH), 6.29 (s, 1H, CH), 3.80 (s, 5H, OMe + CH₂), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 169.8, 162.2, 155.5, 140.8, 140.1, 139.2, 136.9, 135.4, 133.0, 132.7, 131.3, 129.9, 129.6, 128.9, 128.5, 128.4, 128.2, 127.7, 122.2, 120.8, 114.6, 113.9, 112.3, 95.6, 55.5, 34.8, 22.2; HRMS (ESI) m/z calcd for C₃₅H₂₉BrN₃O₃ [M + H]⁺: 618.1387, found: 618.1391.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(4-fluorophenyl)acetamide (9d).

White powder; Mp: 293-294 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.28 (s, 1H, NH), 7.63-7.67 (m, 2H, ArH), 7.54-7.60 (m, 3H, ArH), 7.39-7.48 (m, 7H, ArH), 7.29-7.32 (m, 3H, ArH), 7.18 (d, $J = 6.8$ Hz, 2H, ArH), 6.97 (t, $J = 8.8$ Hz, 2H, ArH), 6.30 (s, 1H, CH), 3.79 (s, 2H, CH₂), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.1, 161.2 (¹ $J_{CF} = 245.2$ Hz), 157.4, 140.8, 140.2, 139.2, 136.8, 135.7, 135.5 (⁴ $J_{CF} = 2.0$ Hz), 132.6, 131.3, 129.9, 129.6, 129.0, 128.4 (³ $J_{CF} = 8.2$ Hz), 127.7, 122.3, 120.9, 120.8, 161.1 (² $J_{CF} = 22.2$ Hz), 114.3, 112.2, 95.7, 34.8, 22.1; HRMS (ESI) m/z calcd for C₃₄H₂₆BrFN₃O₂ [M + H]⁺: 606.1187, found: 606.1196.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(4-chlorophenyl)acetamide (9e).

Pale yellow powder; Mp: 261-262 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.36 (s, 1H, NH), 7.63-7.67 (m, 2H, ArH), 7.59 (d, $J = 7.6$ Hz, 1H, ArH), 7.54 (d, $J = 8.8$ Hz, 2H, ArH), 7.38-7.48 (m, 7H, ArH), 7.38-7.48 (m, 4H, ArH), 7.29-7.31 (m, 4H, ArH), 7.24 (d, $J = 8.4$ Hz, 2H, ArH), 7.18 (d, $J = 6.8$ Hz, 2H, ArH), 6.30 (s, 1H, CH), 3.78 (s, 2H, CH₂), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.2, 162.2, 140.9, 140.2, 139.1, 138.2, 136.8, 135.6, 132.6, 131.4, 129.9, 129.6, 129.0, 128.6, 128.3, 127.8, 127.7, 122.4, 120.6, 114.1, 112.2, 95.7, 34.9, 22.1; HRMS (ESI) m/z calcd for C₃₄H₂₆BrClN₃O₂ [M + H]⁺: 622.0891, found: 622.0898.

N-(4-bromophenyl)-2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)acetamide (9f).

White powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.40 (s, 1H, NH), 7.64 (d, $J = 6.8$ Hz, 2H, ArH), 7.59 (d, $J = 6.0$ Hz, 1H, ArH), 7.19-7.51 (m, 11H, ArH), 7.30 (d, $J = 7.2$ Hz, 2H, ArH), 7.19 (s, 2H, ArH), 6.30 (s, 1H, CH), 3.78 (s, 1H, CH₂), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.3, 162.2, 140.9, 140.2,

139.1, 138.7, 136.8, 135.6, 132.6, 131.6, 131.4, 129.9, 129.6, 129.0, 128.4, 128.3, 127.7, 122.4, 121.0, 115.4, 114.1, 112.2, 95.7, 35.0, 22.1; HRMS (ESI) m/z calcd for $C_{34}H_{26}Br_2N_3O_2$ $[M + H]^+$: 666.0386, found: 666.0396.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(4-(trifluoromethyl)phenyl)acetamide (9g).

Pale yellow crystal; Mp: 282-284 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 11.62 (s, 1H, NH), 7.59-7.71 (m, 4H, ArH), 7.60 (d, $J = 7.6$ Hz, 1H, ArH), 7.29-7.54 (m, 8H, ArH), 7.17-7.19 (m, 4H, ArH), 7.18 (d, $J = 6.4$ Hz, 1H, ArH), 6.31 (s, 1H, CH), 3.81 (s, 2H, CH_2), 2.03 (s, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 170.6, 162.3, 142.7, 140.9, 140.3, 139.1, 136.8, 135.7, 132.6, 132.3, 131.6, 131.4, 129.9, 129.7, 129.6, 129.1, 128.3, 127.6, 125.9, 122.4, 119.0, 113.8, 112.1, 95.7, 35.1, 22.1; HRMS (ESI) m/z calcd for $C_{35}H_{26}BrF_3N_3O_2$ $[M + H]^+$: 656.1155, found: 656.1156.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(3-chlorophenyl)acetamide (9h).

Yellow solid; Mp: 286-288 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 11.47 (s, 1H, NH), 7.65-7.69 (m, 2H, ArH), 7.54-7.59 (m, 3H, ArH), 7.29-7.48 (m, 10H, ArH), 7.18-7.22 (m, 3H, ArH), 7.00 (d, $J = 7.6$ Hz, 1H, ArH), 6.30 (s, 1H, CH), 3.79 (s, 2H, CH_2), 2.03 (s, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 170.4, 162.2, 140.9, 140.8, 140.3, 139.1, 136.8, 135.6, 134.2, 132.6, 132.4, 131.6, 131.4, 130.0, 129.8, 129.6, 129.0, 128.3, 127.7, 123.1, 122.4, 119.4, 117.4, 114.1, 112.1, 95.7, 35.0, 22.1; HRMS (ESI) m/z calcd for $C_{34}H_{26}BrClN_3O_2$ $[M + H]^+$: 622.0891, found: 622.0885.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(2,4-dichlorophenyl)acetamide (9i).

Yellow crystal; Mp: 283-284 °C; 1H NMR (400 MHz, $CDCl_3$, TMS): δ 10.55 (s, 1H, NH), 8.19 (d, $J = 8.4$ Hz, 1H, ArH), 7.57-7.61 (m, 2H, ArH), 7.53 (d, $J = 7.2$ Hz, 1H, ArH), 7.52-7.54 (m, 5H, ArH), 7.29-7.44 (m, 6H, ArH), 7.21 (s, 3H, ArH), 6.29 (s, 1H, CH), 3.94 (s, 2H, CH_2), 2.03 (s, 3H, CH_3); ^{13}C NMR (100 MHz, $CDCl_3$, TMS): δ 171.0, 161.8, 140.4, 140.2, 138.8, 136.9, 135.2, 134.6, 132.5, 131.3, 129.7, 129.6, 129.0, 128.8, 128.6, 128.5, 128.2, 127.6, 127.1, 125.5, 124.8, 122.3, 114.0, 112.4, 95.3, 34.6, 22.2; HRMS (ESI) m/z calcd for $C_{34}H_{25}BrCl_2N_3O_2$ $[M + H]^+$: 656.0502, found: 656.0509.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-

c]pyridin-3-yl)-N-(2,4-dimethylphenyl)acetamide (9j).

White crystal; Mp: 248-250 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.19 (s, 1H, NH), 7.76 (d, *J* = 8.0 Hz, 1H, ArH), 7.56-7.60 (m, 2H, ArH), 7.53 (d, *J* = 6.8 Hz, 1H, ArH), 7.41-7.45 (m, 8H, ArH), 7.20-7.29 (m, 5H, ArH), 6.99 (d, *J* = 8.0 Hz, 1H, ArH), 6.96 (s, 1H, ArH), 6.30 (s, 1H, CH), 3.88 (s, 2H, CH₂), 2.29 (s, 3H, CH₃), 2.16 (s, 3H, CH₃), 2.03 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.6, 161.9, 140.5, 140.1, 139.0, 137.0, 135.3, 134.3, 133.8, 132.7, 131.3, 131.0, 129.7, 129.6, 128.8, 128.5, 128.1, 127.7, 126.6, 123.4, 122.2, 114.9, 112.4, 95.4, 34.4, 22.2, 20.9, 18.3; HRMS (ESI) *m/z* calcd for C₃₆H₃₁BrN₃O₂ [M + H]⁺: 616.1594, found: 616.1597.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(2,6-dimethylphenyl)acetamide (9k).

Yellow solid; Mp: 228-230 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.29 (s, 1H, NH), 7.93 (d, *J* = 8.0 Hz, 1H, ArH), 7.52-7.61 (m, 4H, ArH), 7.41-7.44 (m, 8H, ArH), 7.27-7.31 (m, 3H, ArH), 7.13-7.22 (m, 5H, ArH), 7.02 (d, *J* = 7.2 Hz, 1H, ArH), 6.31 (s, 1H, CH), 3.90 (s, 2H, CH₂), 2.21 (s, 3H, CH₃), 2.02 (s, 6H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.7, 161.9, 140.6, 140.1, 138.9, 137.0, 136.9, 135.3, 132.7, 132.4, 131.6, 131.3, 130.3, 129.9, 129.8, 129.7, 129.6, 128.8, 128.5, 128.3, 128.2, 127.6, 126.1, 124.3, 123.2, 122.2, 114.7, 112.4, 95.5, 34.5, 22.2, 18.5; HRMS (ESI) *m/z* calcd for C₃₆H₃₁BrN₃O₂ [M + H]⁺: 616.1594, found: 616.1593.

2-(2-(4-bromophenyl)-6-methyl-4-oxo-1,5-di-p-tolyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9l).

White crystal; Mp: 263-264 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.14 (s, 1H, NH), 7.42-7.50 (m, 8H, ArH), 7.17-7.29 (m, 4H, ArH), 7.04-7.10 (m, 4H, ArH), 6.25 (s, 1H, CH), 3.78 (s, 2H, CH₂), 2.51 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 2.31 (s, 3H, CH₃), 2.01 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.1, 162.3, 140.8, 140.1, 138.8, 138.1, 137.1, 136.5, 135.4, 134.3, 132.7, 132.5, 131.3, 130.5, 130.2, 129.1, 128.7, 128.1, 127.4, 122.1, 119.4, 114.3, 112.1, 95.5, 34.9, 22.1, 21.3, 21.2, 20.9; HRMS (ESI) *m/z* calcd for C₃₇H₃₃BrN₃O₂ [M + H]⁺: 630.1751, found: 630.1755.

2-(2-(4-bromophenyl)-1,5-bis(4-methoxyphenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9m).

Pale yellow crystal; Mp: 237-238 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.14 (s, 1H,

NH), 7.42-7.50 (m, 6H, ArH), 7.20-7.29 (m, 2H, ArH), 7.08-7.7.14 (m, 6H, ArH), 6.93 (d, $J = 8.4$ Hz, 2H, ArH), 6.22 (s, 1H, CH), 3.94 (s, 3H, OMe), 3.85 (s, 3H, OMe), 3.78 (s, 2H, CH₂), 2.31 (s, 3H, CH₃), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.1, 162.5, 159.6, 159.1, 141.0, 140.4, 137.1, 135.5, 132.7, 132.5, 131.8, 131.3, 129.6, 129.3, 129.2, 128.8, 128.6, 122.1, 119.4, 115.0, 114.7, 114.2, 112.0, 95.5, 55.6, 55.5, 34.9, 22.2, 20.9; HRMS (ESI) m/z calcd for C₃₇H₃₃BrN₃O₄ [M + H]⁺: 662.1649, found: 662.1655.

2-(2-(4-bromophenyl)-1,5-bis(4-fluorophenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9n).

White crystal; Mp: 260-262 °C; ¹H NMR (400 MHz, DMSO-*d*₆, TMS): δ 10.66 (s, 1H, NH), 7.55 (d, $J = 8.0$ Hz, 2H, ArH), 7.30-7.43 (m, 12H, ArH), 7.08 (d, $J = 8.0$ Hz, 2H, ArH), 6.31 (s, 1H, CH), 3.67 (s, 2H, CH), 2.24 (s, 3H, CH₃), 1.95 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆, TMS): δ 169.3, 163.0, 161.8 (¹ $J_{CF} = 243.2$ Hz), 161.3 (^{1'} $J_{CF} = 243.2$ Hz), 141.3, 140.9, 137.3, 135.6, 135.1, 133.1, 133.0, 132.5, 132.3, 131.8, 131.6, 131.3 (³ $J_{CF} = 9.0$ Hz), 130.5 (^{3'} $J_{CF} = 8.0$ Hz), 129.6, 129.3, 122.1, 119.2, 117.1, 116.7 (² $J_{CF} = 22.2$ Hz), 116.5 (^{2'} $J_{CF} = 22.2$ Hz), 114.0, 111.8, 95.0, 34.4, 22.0, 20.8; HRMS (ESI) m/z calcd for C₃₅H₂₇BrF₂N₃O₂ [M + H]⁺: 638.1249, found: 638.1248.

2-(1,5-dibenzyl-2-(4-bromophenyl)-6-methyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9o).

Pale yellow solid; Mp: 261-262 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.16 (s, 1H, NH), 7.59 (d, $J = 8.0$ Hz, 2H, ArH), 7.60 (d, $J = 8.0$ Hz, 2H, ArH), 7.29-7.38 (m, 8H, ArH), 7.19 (s, 2H, ArH), 6.99 (d, $J = 8.0$ Hz, 3H, ArH), 6.20 (s, 1H, CH), 5.55 (s, 2H, CH₂), 5.15 (s, 2H, CH₂), 3.75 (s, 2H, CH₂), 2.36 (s, 3H, CH₃), 2.29 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.0, 161.8, 139.9, 139.8, 137.1, 137.0, 136.9, 135.9, 132.8, 132.4, 131.7, 129.1, 129.0, 128.9, 128.4, 127.7, 127.3, 126.1, 125.8, 123.2, 119.4, 113.5, 112.0, 95.9, 47.9, 47.0, 35.1, 21.4, 20.9; HRMS (ESI) m/z calcd for C₃₇H₃₃BrN₃O₂ [M + H]⁺: 630.1751, found: 630.1751.

2-(2-(4-fluorophenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9p).



Gray powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.15 (s, 1H, NH), 7.64 (d, $J = 7.6$ Hz, 2H, ArH), 7.41-7.65 (m, 10H, ArH), 6.29 (s, 1H, CH), 3.80 (s, 2H,




CH₂), 2.32 (s, 3H, CH₃), 2.02 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.2, 162.2 (¹J_{CF} = 242.2 Hz), 140.6, 139.9, 139.2, 137.1, 137.0, 135.6, 133.1, 133.0, 132.5, 129.9, 129.5, 129.2, 129.0, 128.9, 128.5, 128.3, 128.1, 127.7, 126.2, 125.7, 121.1, 119.3, 115.2 (²J_{CF} = 21.2 Hz), 114.1, 112.2, 95.6, 34.9, 22.1, 20.9; HRMS (ESI) m/z calcd for C₃₅H₂₉FN₃O₂ [M + H]⁺: 542.2238, found: 542.2247.

2-(2-(4-methoxyphenyl)-6-methyl-4-oxo-1,5-diphenyl-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-N-(p-tolyl)acetamide (9q).

White powder; Mp: >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.20 (s, 1H, NH), 7.51-7.67 (m, 7H, ArH), 7.29-7.47 (m, 6H, ArH), 7.19 (d, *J* = 8.0 Hz, 2H, ArH), 7.10 (d, *J* = 8.0 Hz, 2H, ArH), 6.88 (d, *J* = 8.0 Hz, 2H, ArH), 6.29 (s, 1H, CH), 3.82 (s, 5H, OMe + CH₂), 2.32 (s, 3H, CH₃), 2.01 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 170.4, 162.2, 159.1, 140.3, 139.5, 139.3, 137.2, 136.6, 132.5, 132.3, 129.9, 129.8, 129.5, 129.4, 129.2, 129.1, 128.8, 128.5, 128.3, 127.9, 127.8, 125.7, 121.9, 121.1, 119.3, 113.5, 112.2, 95.7, 55.2, 35.0, 22.1, 20.9; HRMS (ESI) m/z calcd for C₃₆H₃₂N₃O₃ [M + H]⁺: 554.2438, found: 554.2440.

¹H and ¹³C NMR Spectra





Current Data
 NAME
 EXPNO
 PROCNO
 F2 - Acquisition
 Date
 Time
 INSTRUM
 PROBHD
 PULPROG
 TD
 SOLVENT
 NS
 DS
 SWH
 FIDRES
 AQ
 RG
 DW
 DE
 TE
 D1
 d11
 DELTA
 TD0
 ===== C
 NUC1
 P1
 PL1
 SF01
 ===== C
 CPDPRG2
 NUC2
 PCPD2
 PL12
 PL13
 PL2
 SF02
 F2 - Process
 SI
 SF
 WDW
 SSB
 LB
 GB
 PC

